Granules India gets USFDA tentative nod for generic ADHD treatment tablets

Granules Pharmaceuticals, Inc., a subsidiary of Granules India, has achieved a significant milestone with the tentative green light from US health authorities for its generic amphetamine extended-release tablets, designed for managing attention deficit hyperactivity disorder.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/naEeM6W
via IFTTT